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TransmissionIncreasing evidence demonstrates the transmissibility of ﬁbrillar species of tau protein, but this has
never been directly tested in neurons, the cell type most affected by formation of tau inclusions in
neurodegenerative tauopathies. Here we show that synthetic tau ﬁbrils made from recombinant
protein not only time-dependently recruit normal tau into neuroﬁbrillary tangle-like insoluble
aggregates in primary hippocampal neurons over-expressing human tau, but also induce neuritic
tau pathology in non-transgenic neurons. This study provides highly compelling support for the pro-
tein-only hypothesis of pathological tau transmission in primary neurons and describes a useful
neuronal model for studying the pathogenesis of tauopathies.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tau, a microtubule-binding protein enriched in axons, accumu-
lates into intracellular hyperphosphorylated aggregates known as
neuroﬁbrillary tangles (NFT) in a wide variety of neurodegenera-
tive diseases, including Alzheimer’s disease, frontotemporal
dementia with Parkinsonism linked to chromosome 17, progres-
sive supranuclear palsy, corticobasal degeneration and Pick’s dis-
ease, which are collectively termed neurodegenerative
tauopathies [1]. It has always been enigmatic what initiates the
conversion of tau from a highly soluble protein without deﬁned
secondary structure into insoluble b-sheet rich ﬁbrils. Recently,
numerous studies have shown that exogenously supplied patho-
logical tau, including synthetic tau ﬁbrils, can drive soluble tau into
tangle-like inclusions in both cell culture systems and mouse mod-
els [2–6], implicating a seeding-recruitment process as well as cell-
to-cell transmission of pathology as possible underlying mecha-
nisms for the initiation and progression of tauopathies. Similar re-
sults have been demonstrated for other amyloidogenic proteins,such as b-amyloid and a-synuclein (a-syn) [7-11], therefore sug-
gesting a unifying pathogenic mechanism for neurodegenerative
diseases involving protein aggregation.
We previously found that synthetic tau ﬁbrils can spontane-
ously enter non-neuronal cells and recruit normal tau into patho-
logical accumulations [5], but it was unclear whether this
phenomenon could also happen in post-mitotic neurons, which
are the more relevant cell type for studying tauopathies. While a
recent study from our lab showed that intracerebral inoculation
of preformed tau ﬁbrils (tau pffs) into transgenic (Tg) mice over-
expressing human mutant P301S tau (PS19 mice) dramatically
accelerated development of tau pathology [6] thereby providing
in vivo evidence for the transmissibility of synthetic tau ﬁbrils, a
study in cultured neurons would provide an in vitro system more
amenable for mechanistic interrogations and investigation of novel
therapies. Here, we demonstrate that synthetic tau ﬁbrils made
from recombinant protein triggered robust aggregation of other-
wise soluble endogenous tau into NFT-like inclusions in primary
neurons dissociated from embryonic mouse hippocampus.
2. Materials and methods
2.1. Recombinant tau puriﬁcation and in vitro ﬁbrillization assays
The cDNAs coding for (1) the longest isoform of wildtype (wt)
human tau with a myc tag at the 30 end (myc-T40), (2) truncated
human tau containing four MT-binding repeats with a myc tag at
Fig. 1. Insoluble tau accumulated in PS19 primary hippocampal neurons after incubation with myc-K18/P301L pffs. (A) PS19 neurons treated with PBS (PBS control) or myc-
K18/P301L ﬁbrils (pff Td) were immunostained with phospho-tau mAb AT8 and conformational mAb MC-1 with or without 1% Triton-X100 extraction during ﬁxing (ext, no
ext, respectively). DAPI staining was used to visualize nuclei (blue). Scale bar: 100 lm. (B) Perikaryal tau aggregates recognized by AT8 and MC-1. Scale bar: 50 lm. (C)
Neurons treated with PBS or myc-K18/P301L ﬁbrils (pff) were sequentially extracted with 1% Triton-X100 lysis buffer (T) followed by 1% SDS lysis buffer (S) and
immunoblotted with AT8, polyclonal antibody against total tau (17025), and mAb against human tau (T14). GAPDH served as loading control. Results from two independent
sets of neurons were shown.
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T40/P301S), (4) 50myc-K18 containing P301L mutation (myc-K18/
P301L) were cloned into pRK172 bacterial expression vector. Each
protein was expressed in BL21 (DE3) RIL cells and puriﬁed by cat-
ionic exchange using a Fast Protein Liquid Chromatography (FPLC)
as previously described [12].
For in vitro ﬁbrillization, 40 lM recombinant tau was incubated
with 40 lM low-molecular-weight heparin and 2 mM DTT in
100 mM sodium acetate buffer (pH 7.0) at 37 C. Myc-T40 and
myc-T40/P301S were agitated at 1000 rpm for 5–7 and 1 day
respectively, but myc-K18 and myc-K18/P301L were incubated
without agitation for 2–3 day. Before they were used for transduc-
tion in neurons, ﬁbrillization mixtures were centrifuged at
100000g for 30 min at 22 C, and the resulted pellet was re-sus-
pended in equal volume of 100 mM sodium acetate buffer (pH 7.0)
without heparin and DTT. Successful ﬁbrillization was veriﬁed by
sedimentation test, ThT test and negative stain electron micros-
copy (EM).
2.2. Primary neuron cultures and ﬁbril transduction
Primary neuron cultures were prepared from E15–E17 embryos
from het/het or homo/het crosses of PS19 mice [13], non-Tg CD1
mice (Charles River, Wilmington, MA) and tau knock-out mice[14]. Dissociated hippocampal neurons were plated onto poly-D-ly-
sine coated 13 mm coverslips or 6-well plates. Pff transduction was
performed at 6 day invitro, whereby tau pffs were diluted in PBS
and sonicated with 60 pulses before being added to neuron med-
ium. Neurons on each coverslip received 1.5 lg of tau pffs and
those on the 6-well plate received 6 lg of pffs per well. Transduced
neurons were harvested for immunocytochemistry or sequential
extraction at 18 day post-pff transduction unless otherwise
indicated.
2.3. Immunocytochemistry
Neurons were ﬁxed in 4% paraformaldehyde (PFA) containing
2% sucrose for 15 min and permeabilized with 0.1% Triton-X100
for 15 min, or ﬁxed with 4% PFA containing 2% sucroseand 1% Tri-
ton-X100 for 15 min to remove soluble proteins. After blocking
with 3% BSA and 3% FBS for at least 1 h at RT, neurons were incu-
bated with speciﬁc primary antibodies (Supplementary Table 1)
overnight at 4 C followed by staining with appropriate Alexaﬂuor
594 or 488-conjugated secondary antibodies (Invitrogen; Carlsbad,
CA) for 2 h at RT. DAPI was added to PBS wash after secondary anti-
body incubation to label cell nuclei. Quantiﬁcation for area occu-
pied by pff-induced pathology was performed on 20 images
using Image J (National Institute of Health).
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Neurons were scraped into Triton lysis buffer (1% Triton-X100
in 50 mM Tris, 150 mM NaCl, pH 7.6) containing phosphatase
and protease inhibitor cocktail, sonicated, and centrifuged
at 100000g for 30 min at 4 C. Pellets were washed once in
Tritonlysis buffer, re-suspended into SDS lysis buffer (1% SDS in
50 mM Tris, 150 mM NaCl, pH 7.6) at a volume that is 1=4 of the
Triton lysis buffer and centrifuged at 100000g for 30 min at
22 C. Supernatants from Triton and SDS extractions were resolved
on SDS–PAGE, transferred to nitrocellulose membranes, and
blocked in 5% milk or 7.5% BSA in TBS before immunoblotted with
speciﬁc antibodies (Supplementary Table 1). 10 lg of proteins from
Triton fractions and equal volume of corresponding SDS fractions
were loaded per lane.
2.5. EM
Negative stain transmission EM (TEM) of tau pffs, TEM and im-
muno-EM of pff transduced primary hippocampal neurons were
performed as previously described [4,9]. Monoclonal antibody
(mAb) MC-1 was used in the immuno-EM of neurons.Fig. 2. Ultrastructural analysis of tau pff-induced aggregates by EM and
immuno-EM. Routine EM (A) revealed ﬁlamentous structures in the cytoplasm of
tau pff-transduced neurons, which were recognized by MC-1 in immuno-EM using
both HRP-labeling (B) and nanogold-ampliﬁcation (C) detecting methods. Scale bar:
500 nm.3. Results
Despite the overexpression of human tau harboring P301S
mutation, primary hippocampal neurons dissociated from PS19
mouse embryos showed phosphorylated tau recognized by AT8
that remained Triton X-100 soluble up to 24 day in vitro
(Fig. 1A). Remarkably, addition of tau pffs consisting of only the
MT-binding domain with P301L mutation (myc-K18/P301L) to
neuron medium at 6 day in vitro, without any transduction re-
agent, led to robust accumulation of phosphorylated tau through-
out soma and neurites that resisted detergent extraction at 18 day
post-transduction (24 day in vitro) (Fig. 1A). In addition, perikar-
yal aggregates in pff-treated neurons were intensely labeled by
disease-speciﬁc conformational antibody MC-1 [15], indicating
pathological conformation acquired by pff-induced aggregates.
Higher magniﬁcation images revealed AT8 and MC-1 labeled
inclusions as bundles of aggregates highly reminiscent of NFTs
ﬁlling up the soma of a subset of neurons (Fig. 1B). Since both
AT8 and MC-1 recognize epitopes absent from myc-K18/P301L
pffs and pff-transduced tau knock-out neurons displayed no
immunoreactivity for any tau antibodies tested (Supplementary
Figs. 1 and 3C), the observed tau aggregates in PS19 neurons must
represent ﬁbrillization of endogenous full-length tau seeded by
exogenous pffs that spontaneously entered neurons. Furthermore,
K18/P301L pffs without a myc tag also induced widespread accu-
mulation of pathological tau within the same time frame, ruling
out non-speciﬁc effects associated with the tag (Supplementary
Fig. 2).
Pff-induced solubility change of endogenous tau was further as-
sessed by sequentially extracting pff-transduced neurons as well as
PBS-treated control neurons into Triton X-100 lysis buffer followed
by SDS lysis buffer and immunoblotting with different tau antibod-
ies. Prominent Triton-soluble tau was present in PBS- and pff-trea-
ted cultures but SDS-soluble tau was recovered only in pff-
transduced neurons (Fig. 1C).
Ultrastructural analysis using routine TEM revealed cytoplasmic
ﬁlaments in neurons treated with pffs (Fig. 2A) but not in PBS-trea-
ted control neurons (data not shown). Immuno-EM with both HRP-
labeling and nanogold-ampliﬁcation demonstrated MC-1 immuno-
reactivity of pff-induced ﬁbrillar accumulations, further supporting
the recruitment of endogenous full-length tau into NFT-like ﬁla-
mentous aggregates (Fig. 2B and C).A time-course analysis demonstrated that the prevalence of
aggregate-bearing cells increased over time, from sparse distribu-
tion at 6 day post-pff addition to about 20% of neurons carrying
perikaryal aggregates at 18 day post-transduction (Fig. 3A). More-
over, diffuse tau accumulations seen as punctate AT8 and MC-1
immunoreactivity at 6 day turned into densely packed aggregates
at 12 day (Fig. 3B), while NFT-like aggregate bundles described ear-
lier were only observed at 18 day post-transduction (Fig. 1C). The
progressive augmentation in insoluble tau aggregates was also evi-
dent on immunoblots of sequentially extracted neuron lysates at
different time points with about 33% of total human tau seques-
tered into Triton-insoluble fraction at 18 day post-transduction
(Fig. 3C).
Interestingly, early inclusions did not contain endogenous
mouse tau recognized by mAb T49, which appeared at 12 day
post-pff transduction and became more abundant after 18 day
incubation in aggregates co-labeled with polyclonal tau antibody
17025 that preferentially recognizes human tau on immunostain-
ing (Fig. 3D). Therefore, mouse tau can be recruited into pff-seeded
aggregates although the process occurred more slowly compared
to overexpressed human tau. Unlike immunostaining by human
tau speciﬁc mAb T14 which completely overlapped with 17025
staining (Supplementary Fig. 3), mouse tau immunoreactivity only
partially colocalized with that of 17025 even at 18 day post-trans-
duction (Fig. 3D), suggesting not all inclusions contained misfolded
mouse tau. The time-dependent emergence of insoluble mouse tau
was also detected on immunoblot, although the insoluble pool only
constituted a very small fraction of total mouse tau (Fig. 3C).
The differential seeding capacity of wt versus mutant and trun-
cated versus full-length tau pffs was compared in PS19 neurons.
Full-length tau pffs carrying P301S mutation (myc-T40/P301S pffs)
were similarly efﬁcient as myc-K18/P301L pffs (Fig. 4A and B). In
contrast, wt tau pffs, both full-length and truncated (myc-T40
Fig. 3. Time-dependent increase in pff-induced tau pathology and recruitment of mouse tau into aggregates. (A) Increasing population of cells developed tau pathology from
6 to 18 day incubation after pff addition. Green: AT8. Blue: DAPI. Scale bar: 100 lm. (B) Morphological difference between 6 and 12 day post-transduction aggregates
immunostained with AT8 and MC-1. Scale bar: 50 lm. (C) Sequentially extracted PS19 neuron lysates at different time points after pff addition (6, 12, 18 day) or at 18 day
after PBS treatment (PBS) and tau knock-out neuron lysates (tau KO) at 18 day post-addition of PBS or pffs were immunoblotted with AT8, 17025, T14 as well as mAb speciﬁc
for mouse tau (T49). (D) Double-labeling of aggregates by T49 and 17025 at different time points after pff addition. Scale bar: 50 lm. For (A, B, D), soluble proteins were
removed by 1% Triton-X100 during ﬁxing.
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with especially pronounced reduction in neuritic pathology than
mutant pffs, although myc-T40 pffs appeared to be slightly more
potent than myc-K18 pffs (Fig. 4A and B).Myc-K18 and myc-K18/P301L pffs were also tested in non-Tg
primary neurons for their capability to seed endogenous mouse
tau ﬁbrillization without overexpressed human mutant tau. Inter-
estingly, wt myc-K18pffs, but not mutant myc-K18/P301L pffs,
Fig. 4. Differential seeding capacity of distinct forms of tau pffs on PS19 and non-Tg primary neurons. (A) Tau pathology (green: AT8) induced in PS19 neurons by myc-K18,
myc-K18/P301L (myc-K18/PL), myc-T40 and myc-T40/P301S (myc-T40/PS) ﬁbrils. Scale bar: 100 lm. (B) Quantiﬁcation of percentage area occupied by AT8-positive
pathology induced by the different pffs (mean + S.E.M.). Number of independent sets of PS19 neurons tested: n = 2 for myc-K18, n = 3 for the other three. ⁄:<0.05. ⁄⁄:<0.005. (C)
Transduction of myc-K18 but not myc-K18/P301L pffs on non-Tg neurons resulted in neuritic tau pathology (green: AT8). Scale bar: 50 lm. For both (A, B) and (C), soluble
proteins were removed by 1% Triton-X100 during ﬁxing.
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tau in the neurites of non-Tg neurons after 18 day incubation
(Fig. 4C). Notably, the amount of tau inclusions induced in non-
Tg neurons was highly limited as compared to that observed in
PS19 neurons, most likely owing to lack of tau overexpressionand mutation. In addition, unlike pff-induced tau pathology that
were throughout the soma and processes of PS19 neurons, mouse
tau aggregation was never found in the soma of pff-transduced
non-Tg neurons, likely due to predominant expression of endoge-
nous tau in the axons.
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The current study demonstrated induction of robust tau aggre-
gation inside primary neurons by the simple addition of synthetic
tau ﬁbrils to neuronal culture medium without any transduction
reagent, suggesting that the previously described phenomenon of
spontaneous uptake of ﬁbrillar tau and templated conversion of
normal tau into pathological aggregates [2–4] is also applicable
to neurons, the cell type most relevant for neurodegenerative tau-
opathies. Importantly, pff-induced tau aggregation also occurred in
non-Tg neurons in the absence of overexpression, albeit to a much
less extent than in PS19 neurons which overexpress mutant tau,
suggesting that the seeding-recruitment process can indeed take
place at physiological conditions and underlie the etiology of NFT
formation in tauopathies.
As a highly soluble protein, tau resists aggregation under nor-
mal conditions. It was therefore a breakthrough in the ﬁeld when
polyanionic cofactors, such as heparin, RNA, and fatty acids, were
found to greatly promote in vitro ﬁbrillization of tau [16-18]. Even
though tau pffs can dramatically accelerate the kinetics of in vitro
ﬁbril assembly by acting as seeds, efﬁcient seeding reaction still re-
quires the presence of cofactors [19]. Curiously, tau pffs alone are
sufﬁcient to drive aggregation of soluble tau inside the cells with-
out the addition of any cofactor, especially considering the fact that
pffs we added to neurons were re-suspended in heparin-free buf-
fer. Therefore, intracellular environment appears to be more per-
missive for seeded ﬁbrillization than a cell-free system.
Consequently, while polyanionic cofactors may catalyze the initial
formation of misfoded tau seeds in human brains, their involve-
ment in NFT genesis may not be obligatory, since seeded ﬁbrilliza-
tion of tau is a self-perpetuating process in cells once pathological
conformers are generated.
Although mutant tau pffs resulted in dramatically more abun-
dant pathology than wt tau pffs in PS19 neurons overexpressing
mutant tau, they showed even lower seeding capacity than wt pffs
in non-Tg neurons expressing wt mouse tau. The asymmetrical
seeding between wt and P301L mutant tau was also observed in
our previous non-neuronal model albeit less dramatically [5]. To-
gether with the ﬁnding that NFTs in human patients harboring
P301L mutation are nearly exclusively composed of mutant tau
[20], these studies point to possible conformational disparities be-
tween wt and mutant tau ﬁbrils. Since we have never detected
obvious differences in the morphologies of the two types of ﬁbrils
at EM level, we speculate any structural differences are likely more
subtle as suggested by a previous study [21].
Interestingly, full-length wt tau (myc-T40) pffs showed a ten-
dency to seed better than truncated wt (myc-K18) pffs despite
equal mass thus a lower molarity of the former being added to
PS19 neurons. In our previous study when transduction reagent
was used to facilitate pff uptake in non-neuronal cells[5], wt T40
pffs actually demonstrated less efﬁcient seeding than wt K18 pffs
(unpublished data), therefore the observed difference between
full-length and truncated tau pffs in primary neurons is probably
not due to differential recruiting capacity per se, but possibly due
to more efﬁcient uptake of full-length pffs. With the N-terminus
of tau shown to be critical for extracellular secretion [22], it would
be interesting to explore whether the same domain is playing a
role in the uptake of ﬁbrillar tau into neurons.
Unlike the recently developed neuronal model of synucleinopa-
thies in which robust Lewy body- and Lewy neurite-like accumula-
tions composed of mouse a-syn can be induced in non-Tg neurons
by a-syn pffs [9], low abundance of tau aggregates form upon wt
tau pff transduction on non-Tg neurons. The difference could be
attributed to several reasons. First, non-Tg mice naturally express
a-syn of the A53T variant which is a pathogenic mutation in hu-man. Not only does A53T mutation greatly enhance ﬁbrillization
of a-syn [23], but mouse a-syn even ﬁbrillizes much more readily
than human a-syn carrying the A53T mutation (unpublished data).
Lack of such a ‘natural’ mutation in mouse tau limits the extent of
tau pathology that can develop within our experimental time win-
dow. Second, a-syn is highly concentrated at presynaptic terminals
in mature neurons [24] and the local high concentration probably
facilitates efﬁcient recruitment by internalized pff seeds. In con-
trast, tau is more diffusely located throughout axons in non-Tg
neurons. Third, the adult isoform of tau with four repeats (4R) only
constitutes a small fraction of total tau in developing neurons
[25,26], while the predominantly expressed 3R-tau has lower pro-
pensity to aggregate than 4R-tau [27] in addition to a seeding bar-
rier between 3R- and 4R-tau as previously reported [28].
Nonetheless, seeding endogenous mouse tau in non-Tg neurons
provides a more physiological system for studying tau aggregation
and pathology spreading.
In summary, our study directly demonstrates the transmissibil-
ity of ﬁbrillar tau in neurons, thereby presenting a neuronal model
suitable for both mechanistic studies on the pathogenesis of NFTs
and therapeutic investigation to identify drugs that can reverse
or prevent tau pathology.
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